Some Aspects on the Management of Hemophilia

• References

• 1 Kemoff P. Current Factor VIII Usage Related to Self Sufficiency: A European Overview. Factor VIII: Purity and Prophylaxis Royal Society of Medicine Services 1991; Roundtable Series No. 25: 4
• 2 Pettersson H, Gilbert M. Musculoskeletal and other haemorrhagic complications. In Diagnostic Imaging in Hemophilia Berlin: Springer-Verlag; 1985: 55-60
• 3 Aledort LM, Haschmeyer RH, Pettersson H. The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VUI-deficient haemophiliacs Journal of Internal Medicine 1994; 236: 391-399
• 4 Nilsson IM, Bemtorp E, Löfqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. Journal of Internal Medicine 1992; 232: 25-32
• 5 Mannucci PM, Ruggeri ZM, Pareti FI, Capitano A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand’s disease. Lancet 1977; 1: 869-872
• 6 Mannucci PM. Desmopressin (DDAVP) for treatment of disorders of hemostasis. In: Coller BS. (ed) Progress in hemostasis and thrombosis. Gnine and Stratton. Orlando,FL: 1986: 19-45
• 7 Lethargen S, Harris AS, Sjörin E, Nilsson IM. Intranasal and intravenous administration of desmopression: Effect on FVIII/FWF, pharmacokenetics and reproducibility. Thromb Haemost 1987; 58: 1033-1036
• 8 Rose EH, Aledort LM. Nasal Spray Desmopressin (DDAVP) for Mild hemophilia A and von Willebrand disease. Annals Internal Medicine 1991; 114: 563-568
• 9 Seremetis SV, Aledort LM. Nasal Spray desmopressin (DDAVP) experience in home care and surgical prophylaxis. In Abstracts 7 the XXI International Congress of the World Federation of Hemophilia Abstract 206 24-29 04/1994. Mexico City, Mexico:
• 10 Christolini A, Drogoni F, Ferrari A, LaVerde G, Avcieri R, Mohamud AE, Mazzucconi MG. Intranasal DDAVP Biological and clinical evaluation in mild factor VIII deficiency. Haemostasis 1991; 21: 273-277